



BAFNA PHARMACEUTICALS LTD.,

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.
PHONE:+044-25267517/25270992, FAX:91-44-25231264, Email: info@bafnapharma.com, website: www.bafnapharma.com

22.05.2013

Ref: No. BPL/ 93 /2013-14

Listing Department
The Bombay Stock Exchange Limited
P J Towers
Dalal Street
Mumbai - 400 001
SCRIP CODE: 532989

Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E)
Mumbai - 400051
SCRIP SYMBOL: BAFNAPHARM

ISIN: INE 878I01014

Dear Sir

Sub: Media release on Results

As you are aware the Board of Directors has approved the Audited Financial Results of the Company for the Financial Year ended 31st Mach, 2013 on Standalone & Consolidated basis at its meeting held on 20.05.2013.

In connection with the above, please find attached the copy of media release.

This is for your kind information & records and dissemination to all the concerned. Kindly treat this as compliance with the Listing Agreement.

Thanking you

Yours faithfully

For BAFNA PHARMACEUTICALS LIMITED


K.Premnath
Company Secretary

Encl: as above.



Bafna Pharmaceuticals Ltd. recommends 6 % dividend for 2012-13

Chennai, 22 May 2013: The Board of Directors of Bafna Pharmaceuticals Ltd, (BSE Code: 532989), NSE (BAFNAPHARM) a Chennai-based Pharma company engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non–Betalactum, at its meeting held on May 20, 2013 have recommended 6% dividend.

Mr. Bafna Mahaveer, CMD, Bafna Pharmaceuticals Ltd. said, “We have always been committed to our customers and stakeholders. The financial results for this fiscal are the testimony of our vision. We have aggressive plans to boost our exports in the times to come along with strong domestic presence with our brand ‘RARICAP’.”

The sales of Raricap during FY 2012-13 is Rs 16.15 crore against the sales of Rs 7.78 crore in FY 2011-12. Within 2nd year of launch, Raricap has reached 22nd position as per AIOCD (Mar ‘13 MAT Value) in haematinic segment.

Key highlights of the approved Audited financial results for the year ended March 31, 2013 are:

On a standalone basis,

- (a) Total income has increased by 34.84% to Rs.167.13 crore compared to Rs.123.95 crore in the previous year and
- (b) Net Profit has increased by 87.03% to Rs.3.88 crore compared to Rs.2.07 crore in the previous year.

On a consolidated basis,

- (a) Total Income has increased by 36.65 % to Rs.175.77 crore compared to Rs. 128.63 crore in the previous year and
- (b) Net Profit rose by 115.22% to Rs.3.96 crore compared to Rs.1.84 crore in the previous year.

**About Bafna Pharmaceuticals Ltd:**

The company has 173 products registered in UK, Sri Lanka, Nepal, Ukraine, Ghana, Ethiopia, Philippines, Kryghistan, Georgia, Honduras, Colombia, Uzbekhistan, Vietnam and Nigeria. The company has two manufacturing facilities. A WHO-GMP certified manufacturing facility in Madhavaram, which is a 100 percent Export oriented Unit (EOU) and an EU GMP (UK MHRA), facility at Grantlyon, Chennai. Recently, the company received Australian TGA approval and also received the Good Manufacturing Practices (GMP) approval from Ethiopia's Drug Administration and Control Authority (DACA) for its non-betalactam facility.

The company in the month of April 2010 inaugurated its Research and Development (Formulation) (FR&D) facility, a pilot plant in Chennai. The company has secured ISO 9001: 2008 Certificate of Registration for Manufacture and Export of Pharmaceutical products. BafnaPharma has also received EU GMP Compliances from (MHRA) Medicines and Healthcare products Regulatory Agency, U.K. This accreditation has made Bafna Pharmaceuticals the 35th facility to achieve this key recognition in India and has opened the gates for exploring markets of European Union.

BafnaPharma has recently acquired marquee brand "RARICAP" from Johnson & Johnson Associate Company.

For more information please contact:

MohsinVadgama

Manager, Minepro Communications

Email- mohsin@mineprocomm.com

Mob- 08484848485